Vanda Pharmaceuticals Gains Ownership Of The U.S. NDA And IND Applications For PONVORY From A Johnson & Johnson Company, Which Now Fully Allows Vanda To Commercialize PONVORY In The U.S.
Vanda Pharmaceuticals Inc. 0.00%
Vanda Pharmaceuticals Inc. VNDA | 4.73 | 0.00% |
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that ownership of the U.S. New Drug Application and Investigational New Drug Applications for PONVORY® (ponesimod) has been transferred to Vanda from a Johnson & Johnson Company, which now fully allows Vanda to commercialize PONVORY® in the U.S.